Inglot Małgorzata, Szymczak Aleksandra, Gładysz Andrzej, Małyszczak Krzysztof, Zalewska Małgorzata
Katedra i Klinika Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów Odpornościowych AM we Wrocławiu.
Przegl Epidemiol. 2007;61(3):535-43.
analysis of data characterizing HCV infection in patients infected with HIV.
37 persons (29 male and 8 female) aged 23-49 years (mediana 34), with HIV/HCV coinfection, treated (n=25) and untreated (n=12) with antiretroviral therapy. HAART was effective in treated patients; CD4+ count >350 cells/microl. Viral load of HIV and HCV, HCV genotypes, CD4/CD8, biochemical tests, histopathological examination were measured. Results were analyzed statistically.
the majority of patients were former IVDUs (n=31.84%), 3 persons (8%)--MSM, 3 (8%)--route of infection unknown. Duration of HCV infection 1-10 years, mediana 5. All patients were in A1 or A2 stage of HIV infection. Among patients treated with HAART (n=25) mediana of CD4+ count before treatment was 263 (69-595) cells/micro, mediana of HIV viral load 75000 copies/ml (n=7); 2040-263414 copies/ml. 17 patients were currently treated with PI, 17 with NNRTI, and 2 patients with NRTI only. HCV genotype was determined in 32 patients: 3a--n=19 (59%), 1--n= 9 (28%) 4--n=4 (13%). HCV viral load: 2.4 x 10(5)-7.73 x 10(6) IU/ml, mediana 1.6 x 10(6). Levels of ALT: 21-358 IU/ml, mediana 102, AST: 20-195 IU/ml, mediana 62, GGTP--9-463 IU/ml, mediana 58. ALT level was significantly higher in HCV genotype 3a infection (p=0.0214). Fibrosis stage above 2 was revealed in 3 patients and in majority (62%) was below 2. None patient had liver cirrhosis. Fibrosis was significantly higher in patients with low CD4+ nadir (p=0.03).
Progression of liver fibrosis is slow in patients coinfected with HIV/HCV with high CD4+ count. High percentage of HCV genotype 3 and mild fibrosis are good prognostic factors for effectiveness of HCV infection treatment in HIV infected persons.
分析感染人类免疫缺陷病毒(HIV)患者的丙型肝炎病毒(HCV)感染特征数据。
37例年龄在23 - 49岁(中位数34岁)的患者,合并感染HIV/HCV,其中25例接受抗逆转录病毒治疗,12例未接受治疗。高效抗逆转录病毒治疗(HAART)对接受治疗的患者有效;CD4 + 细胞计数>350个/微升。检测HIV和HCV的病毒载量、HCV基因型、CD4/CD8比值、生化检查及组织病理学检查。对结果进行统计学分析。
大多数患者为既往静脉注射毒品者(n = 31.84%),3例(8%)为男男性行为者,3例(8%)感染途径不明。HCV感染持续时间为1 - 10年,中位数为5年。所有患者均处于HIV感染的A1或A2期。在接受HAART治疗的患者中(n = 25),治疗前CD4 + 细胞计数中位数为263(69 - 595)个/微升,HIV病毒载量中位数为75000拷贝/毫升(n = 7);2040 - 263414拷贝/毫升。17例患者目前接受蛋白酶抑制剂(PI)治疗,17例接受非核苷类逆转录酶抑制剂(NNRTI)治疗,2例仅接受核苷类逆转录酶抑制剂(NRTI)治疗。32例患者确定了HCV基因型:3a型 - n = 19(59%),1型 - n = 9(28%),4型 - n = 4(13%)。HCV病毒载量:2.4×10⁵ - 7.73×10⁶国际单位/毫升,中位数为1.6×10⁶。谷丙转氨酶(ALT)水平:21 - 358国际单位/毫升,中位数为102,谷草转氨酶(AST):20 - 195国际单位/毫升,中位数为62,γ-谷氨酰转肽酶(GGTP) - 9 - 463国际单位/毫升,中位数为58。HCV 3a型感染患者的ALT水平显著更高(p = 0.02